Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update
Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update ACCESSWIRE SON-1010, fully-human IL-12 configured using F HAB platform, advancing towards IND submission At-The-Market offering program resulted in net proceeds of $10.2 million PRINCETON, NJ / ACCESSWIRE / May 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ('Sonnet' or the 'Company'), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended March 31, 2021 and provided a business update. 'Over the course...